Citations

Clear

1434 citation(s) found for "Uk, Nathan".

Factors Associated With Physical Activity Levels in Patients With Breast Cancer
Marell, Paulina S. , Herrmann, Joerg , D’Andre, Stacy D, Cheville, Andrea , Barksdale, Toure, Loprinzi, Charles L. , Ruddy, Kathryn J. , Cheville, Andrea L , Ruddy, Kathryn J , Vierkant, Robert A. , Olson, Janet E. , Larson, Nicole , LeBrasseur, Nathan K. , Barksdale, Touré, Couch, Fergus J.

Mayo Clinic

The Oncologist | August 10, 2022 | Volume: 27 | Issue: 10 | Pages: e811-e814

10.1093/oncolo/oyac159 | PMID 35946834 Get It

Abstract Physical activity (PA) is associated with improvement in breast cancer treatment-related symptoms and survival, yet most breast cancer survivors do not meet national PA guidelines. This study aimed to identify characteristics of participants that were associated with an increased likelihood of meeting PA guidelines. Adults with breast cancer seen at Mayo Clinic (Rochester, MN) were surveyed regarding their PA participation, and those who self-reported at least 150 minutes of moderate and/or strenuous aerobic PA weekly on average were considered to be “meeting guidelines”. Three thousand participants returned PA data. Younger age, completion of the survey 7-12 years after diagnosis, absence of recurrence, no bilateral mastectomy, absence of metastatic disease, and lower BMI at the time of survey completion were associated with PA participation (P < .05 in univariate and multivariate analyses). Findings were similar when a threshold of 90 minutes was applied. These results may inform the development of targeted PA-facilitating interventions.
Dedicated convolutional neural network for noise reduction in ultra-high-resolution photon-counting detector computed tomography
Huber, Nathan R. , Ferrero, Andrea , Rajendran, Kishore , Glazebrook, Katrina N. , Yu, Lifeng , Baffour, Francis , Diehn, Felix E. , Inoue, Akitoshi , Rajendran, Kishore , Huber, Nathan Robert , Fletcher, Joel G. , Yu, Lifeng , Leng, Shuai , McCollough, Cynthia H.

Mayo Clinic

Physics in Medicine & Biology | August 9, 2022 | Volume: 67 | Issue: 17 | Pages: 175014

10.1088/1361-6560/ac8866 | PMID 35944556 Get It

Abstract Objective. To develop a convolutional neural network (CNN) noise reduction technique for ultra-high-resolution photon-counting detector computed tomography (UHR-PCD-CT) that can be efficiently implemented using only clinically available reconstructed images. The developed technique was demonstrated for skeletal survey, lung screening, and head angiography (CTA). Approach . There were 39 participants enrolled in this study, each received a UHR-PCD and an energy integrating detector (EID) CT scan. The developed CNN noise reduction technique uses image-based noise insertion and UHR-PCD-CT images to train a U-Net via supervised learning. For each application, 13 patient scans were reconstructed using filtered back projection (FBP) and iterative reconstruction (IR) and allocated into training, validation, and testing datasets (9:1:3). The subtraction of FBP and IR images resulted in approximately noise-only images. The 5-slice average of IR produced a thick reference image. The CNN training input consisted of thick reference images with reinsertion of spatially decoupled noise-only images. The training target consisted of the corresponding thick reference images without noise insertion. Performance was evaluated based on difference images, line profiles, noise measurements, nonlinear perturbation assessment, and radiologist visual assessment. UHR-PCD-CT images were compared with EID images (clinical standard). Main results. Up to 89% noise reduction was achieved using the proposed CNN. Nonlinear perturbation assessment indicated reasonable retention of 1 mm radius and 1000 HU contrast signals (>80% for skeletal survey and head CTA, >50% for lung screening). A contour plot indicated reduced retention for small-radius and low contrast perturbations. Radiologists preferred CNN over IR for UHR-PCD-CT noise reduction. Additionally, UHR-PCD-CT with CNN was preferred over standard resolution EID-CT images. Significance. CT images reconstructed with very sharp kernels and/or thin sections suffer from increased image noise. Deep learning noise reduction can be used to offset noise level and increase utility of UHR-PCD-CT images.
The Advisory Group on Risk Evidence Education for Dementia: Multidisciplinary and Open to All
Rosen, Allyson , AGREEDementia, members of, Arias, Jalayne J. , Ashford, J. Wesson , Blacker, Deborah , Chhatwal, Jasmeer P. , Chin, Nathan , Clark, Lindsay R. , Denny, Sharon, Gleason, Carey E. , Heidebrink, Judith L. , Henderson, Victor W. , Lavacot, James A., Lingler, Jennifer H. , Menon, Malavika, Nosheny, Rachel L. , Oliveira, Fabricio Ferreira de , Parker, Monica W. , Rahman‐Filipiak, Annalise , Revoori, Anwita, Rumbaugh, Malia, Sanchez, Danurys , Schindler, Suzanne E. , Toy, Leslie, Tyrone, Jamie, Walter, Sarah , Wang, Li-san, Zallen, Doris T. , Aggarwal, Neelum T. , AGREEDementia, members of, Chin, Nathan A., Goldman, Jill , Grill, Joshua D. , Menon, Malavika, Schwarz, Christopher G. , Wijsman, Ellen M.

Mayo Clinic

Journal of Alzheimer's Disease | August 2, 2022 | Volume: 90 | Issue: 3 | Pages: 953-962

10.3233/jad-220458 | PMID 35938255 Get It

The brain changes of Alzheimer’s disease and other degenerative dementias begin long before cognitive dysfunction develops, and in people with subtle cognitive complaints, clinicians often struggle to predict who will develop dementia. The public increasingly sees benefits to accessing dementia risk evidence (DRE) such as biomarkers, predictive algorithms, and genetic information, particularly as this information moves from research to demonstrated usefulness in guiding diagnosis and clinical management. For example, the knowledge that one has high levels of amyloid in the brain may lead one to seek amyloid reducing medications, plan for disability, or engage in health promoting behaviors to fight cognitive decline. Researchers often hesitate to share DRE data, either because they are insufficiently validated or reliable for use in individuals, or there are concerns about assuring responsible use and ensuring adequate understanding of potential problems when one’s biomarker status is known. Concerns include warning people receiving DRE about situations in which they might be compelled to disclose their risk status potentially leading to discrimination or stigma. The Advisory Group on Risk Evidence Education for Dementia (AGREEDementia) welcomes all concerned with how best to share and use DRE. Supporting understanding in clinicians, stakeholders, and people with or at risk for dementia and clearly delineating risks, benefits, and gaps in knowledge is vital. This brief overview describes elements that made this group effective as a model for other health conditions where there is interest in unfettered collaboration to discuss diagnostic uncertainty and the appropriate use and communication of health-related risk information.
Phase II Study of Enzalutamide for Patients With Androgen Receptor–Positive Salivary Gland Cancers (Alliance A091404)
Ho, Alan L. , Foster, Nathan R. , Zoroufy, Alexander , Campbell, Jordan D., Price, Katharine A., Adkins, Douglas R. , Bowles, Daniel W. , Kang, Hyunseok , Sherman, Eric J. , Morton, Roscoe F., Nadeem, Zaineb , Katabi, Nora , Münster, Pamela N. , Price, Katharine, Adkins, Douglas , Bowles, Daniel W , Kang, Hyunseok , Burtness, Barbara , Sherman, Eric , Morris, Luc G T , Munster, Pamela , Ho, Alan L , Worden, Francis P. , Burtness, Barbara , Schwartz, Gary K.

Mayo Clinic

Journal of Clinical Oncology | July 22, 2022 | Volume: 40 | Issue: 36 | Pages: 4240-4249

10.1200/jco.22.00229 | PMID 35867947 Get It

PURPOSE The androgen receptor (AR) is expressed (+) in a subset of salivary gland cancers (SGCs). This phase II trial evaluated the efficacy of the antiandrogen enzalutamide in AR+ SGC. METHODS Patients with locally advanced/unresectable or metastatic AR+ SGCs were enrolled. Enzalutamide (160 mg) was given orally once daily. The primary end point was the best overall response rate per RECIST v1.1 within eight cycles. Confirmed responses in ≥ 5 of 41 patients would be considered promising. Secondary end points were progression-free survival, overall survival, and safety. RESULTS Forty-six patients were enrolled; 30 (65.2%) received prior systemic therapy, including 13 (28.3%) with AR-targeted drugs. Of seven (15.2%) partial responses (PRs), only two (4.3%) were confirmed per protocol and counted toward the primary end point. Twenty-four patients (52.2%) had stable disease; 15 (32.6%) had progression of disease as best response. Twenty-six patients (56.5%) experienced tumor regression in target lesions; 18 (39.1%) had partial response/stable disease ≥ 6 months. Tumor regressions were observed in female patients (5 of 6 [83.3%]) and those who received prior AR– (6 of 13 [46.2%]) or human epidermal growth factor receptor 2–targeted therapies (5 of 8 [62.5%]). Three patients remained on treatment at data cutoff (duration, 32.2-49.8 months). The median progression-free survival was 5.6 months (95% CI, 3.7 to 7.5); the median overall survival was 17.0 months (95% CI, 11.8 to 30.0). The most common adverse events were fatigue, hypertension, hot flashes, and weight loss. Total and free testosterone levels increased by a mean of 61.2% and 48.8%, respectively, after enzalutamide. CONCLUSION Enzalutamide demonstrated limited activity in AR+ SGC, failing to meet protocol-defined success in part because of a lack of response durability. Strategies to enhance the efficacy of antiandrogen therapy are needed.
Detecting Sources of Immune Activation and Viral Rebound in HIV Infection
Wietgrefe, Stephen W. , Duan, Lijie, Anderson, Jodi, Marqués, Guillermo , Sanders, Mark A , Cummins, Nathan W. , Karn, Jonathan , Pagliuzza, Amélie , Chomont, Nicolas , Sannier, Gérémy , Kaufmann, Daniel E. , Zuck, Paul, Howell, Bonnie J. , Reilly, Cavan , Herschhorn, Alon , Schacker, Timothy W. , Haase, Ashley T. , Cummins, Nathan W , Badley, Andrew D. , Dobrowolski, Curtis N. , Dubé, Mathieu , Wu, Guoxin

Mayo Clinic

Journal of Virology | July 20, 2022 | Volume: 96 | Issue: 15 | Pages: No page available

10.1128/jvi.00885-22 | PMID 35856674 Get It

Anti-retroviral therapy (ART) has greatly improved the quality and length of life for people living with HIV, but immune activation does not normalize during ART, and persistent immune activation has been linked to increased morbidity and mortality. We report a comparison of assays of two potential sources of immune activation during ART: rare cells producing HIV and the virus’ major viral protein, p24, benchmarked on a cell model of active and latent infections and a method to visualize HIV-producing cells.
GLS1 is a Protective Factor in Patients with Ovarian Clear Cell Carcinoma and its Expression Does Not Correlate with ARID1A-mutated Tumors
Clemente, Valentino , Hoshino, Asumi , Shetty, Mihir , Erickson, Britt , Baker, R. W. R. , Khalifa, Mahmoud A. , Weroha, S. John , Lou, Emil , Bazzaro, Martina , Erickson, Britt K , Lou, Emil , Nelson, Andy , Baker, Ruth, Rubin, Nathan

Mayo Clinic

Cancer Research Communications | July 18, 2022 | Volume: 2 | Issue: 8 | Pages: 784-794

10.1158/2767-9764.crc-22-0122 | PMID 36082022 Get It

Targeting glutamine metabolism has emerged as a novel therapeutic strategy for several human cancers, including ovarian cancer. The primary target of this approach is the kidney isoform of glutaminase, glutaminase 1 (GLS1), a key enzyme in glutamine metabolism that is overexpressed in several human cancers. A first-in-class inhibitor of GLS1, called CB839 (Telaglenastat), has been investigated in several clinical trials, with promising results. The first clinical trial of CB839 in platinum-resistant patients with ovarian cancer is forthcoming. ARID1A-mutated ovarian clear cell carcinoma (OCCC) is a relatively indolent and chemoresistant ovarian cancer histotype. In OCCC-derived cells ARID1A simultaneously drives GLS1 expression and metabolism reprograming. In ARID1A-mutated OCCC-derived mouse models, loss of ARID1A corresponds to GLS1 upregulation and increases sensitivity to GLS1 inhibition. Thus, targeting of GLS1 with CB839 has been suggested as a targeted approach for patients with OCCC with tumors harboring ARID1A mutations. Here, we investigated whether GLS1 is differentially expressed between patients with OCCC whose tumors are ARID1A positive and patients whose tumors are ARID1A negative. In clinical specimens of OCCC, we found that GLS1 overexpression was not correlated with ARID1A loss. In addition, GLS1 overexpression was associated with better clinical outcomes. Our findings have implications for human trials using experimental therapeutics targeting GLS1. Significance: GLS1 differential expression in patients with OCCC with or without ARID1A mutations is significant because a clinical trial with a GLS1 inhibitor is forthcoming. Tumors without ARID1A have low levels of GLS1 and GLS1 expression is associated to better outcome. Thus, blockade of GLS1 could be counterproductive for patients with OCCC.
When is enteral nutrition indicated?
Bechtold, Matthew L. , Escuro, Arlene A. , Grenda, Brandee, Johnston, Theresa, Kozeniecki, Michelle , Limketkai, Berkeley N. , Nelson, Krystie K., Powers, Jan , Ronan, Andrea, Schober, Nathan, Strang, Brian J., Swartz, Cristina, Turner, Justine , Tweel, Lauren , Walker, Renee, Epp, Lisa , Escuro, Arlene , Kozeniecki, Michelle , Limketkai, Berkeley N , Malone, Ainsley , Brown, Patricia M., Johnston, Theresa, Malone, Ainsley

Mayo Clinic

Journal of Parenteral and Enteral Nutrition | July 15, 2022 | Volume: 46 | Issue: 7 | Pages: 1470-1496

10.1002/jpen.2364 | PMID 35838308 Get It

AbstractEnteral nutrition (EN) is a vital component of nutrition around the world. EN allows for delivery of nutrients to those who cannot maintain adequate nutrition by oral intake alone. Common questions regarding EN are when to initiate and in what scenarios it is safe. The answers to these questions are often complex and require an evidence‐based approach. The Board of Directors of the American Society for Parenteral and Enteral Nutrition (ASPEN) established an Enteral Nutrition Committtee to address the important questions surrounding the indications for EN. Consensus recommendations were established based on eight extremely clinically relevant questions regarding EN indications as deemed by the Enteral Nutrition Committee. These consensus recommendations may act as a guide for clinicians and stakeholders on difficult questions pertaining to indications for EN. This paper was approved by the ASPEN Board of Directors.
Considerations for determining the efficacy of new antiseizure medications in children age 1 month to younger than 2 years
French, Jacqueline A. , Cleary, Elena, Dlugos, Dennis , Farfel, Gail, Farrell, Kathleen , Grzeskowiak, Caitlin L. , Gurrell, Rachel , Harden, Cynthia L., Stalvey, Tracy, Tsai, Julia , Blum, David , Fountain, Nathan B. , Grzeskowiak, Caitlin L , Wirrell, Elaine C , Fountain, Nathan , French, Jacqueline , Gidal, Barry E. , Wirrell, Elaine

Mayo Clinic

Epilepsia | July 15, 2022 | Volume: 63 | Issue: 10 | Pages: 2664-2670

10.1111/epi.17366 | PMID 35835554 Get It

AbstractObjectivesDrug treatment for children with epilepsy should, ideally, be governed by evidence from adequate and well‐controlled clinical studies. However, these studies are difficult to conduct, and so direct evidence supporting the informed use of specific drugs is often lacking. The Research Roundtable for Epilepsy (RRE) met in 2020 to align on an approach to therapy development for focal seizures in children age 1 month <2 years of age.MethodsThe RRE reviewed the regulatory landscape, epidemiology, seizure semiology, antiseizure medicine pharmacology, and safety issues applicable to this population.ResultsAfter reviewing evidence, the conclusion was that pediatric efficacy trials would be impracticable to conduct but a waiver of the regulatory requirement to conduct any study would lead to an absence of information to guide dosing in a critical population. Review of available data and discussion of RRE attendees led to the conclusion that the requirements for extrapolation of efficacy from older children down to infants from age 1 month to <2 years old appeared to be met. After the RRE, the US Food and Drug Administration (FDA) approved brivaracetam for use in children with focal epilepsy above the age of 1 month in August 2021 and lacosamide in October 2021, both based on the principle of extrapolation from data in older children.SignificanceThese recommendations should result in more rapid accessibility of antiseizure medications for infants.
Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Mehren, Margaret von , Kane, John M. , Agulnik, Mark , Carr, Janai R. , Connelly, Mary, Ganjoo, Kristen N. , Holder, Ashley M. , Homsi, Jade , Keedy, Vicki L. , Kelly, Ciara M. , Kim, Edward , McCarter, Martin D. , McGarry, Sean V., Mesko, Nathan W. , Meyer, Christian F. , Pappo, Alberto S. , Petersen, Ivy A. , Poppe, Matthew M. , Riedel, Richard F. , Schuetze, Scott M. , Shabason, Jacob E. , Zimel, Melissa N. , Hang, Lisa E., Sundar, Hema, Bergman, Mary Anne, Riedel, Richard F , von Mehren, Margaret , Bui, Marilyn M. , Choy, Edwin , Connelly, Mary, Dry, Sarah , González, Ricardo , Liebner, David A. , Parkes, Amanda , Pollack, Seth M. , Sicklick, Jason Keith , Spraker, Matthew B.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | July 13, 2022 | Volume: 20 | Issue: 7 | Pages: 815-833

10.6004/jnccn.2022.0035 | PMID 35830886 Get It

Soft tissue sarcomas (STS) are rare malignancies of mesenchymal cell origin that display a heterogenous mix of clinical and pathologic characteristics. STS can develop from fat, muscle, nerves, blood vessels, and other connective tissues. The evaluation and treatment of patients with STS requires a multidisciplinary team with demonstrated expertise in the management of these tumors. The complete NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Soft Tissue Sarcoma provide recommendations for the diagnosis, evaluation, and treatment of extremity/superficial trunk/head and neck STS, as well as retroperitoneal/intra-abdominal STS, desmoid tumors, and rhabdomyosarcoma. This portion of the NCCN Guidelines discusses general principles for the diagnosis and treatment of retroperitoneal/intra-abdominal STS, outlines treatment recommendations, and reviews the evidence to support the guidelines recommendations.